Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Stephenson

Showing results (211-220 of 241) with videos related to

Pageof 25
Sort By:
Nature|November 15, 2016
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysErica N Borducchi, Crystal Cabral, Kathryn E Stephenson, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
The European Respiratory Journal|July 13, 2023
Oxidised IL-33 drives COPD epithelial pathogenesis <i>via</i> ST2-independent RAGE/EGFR signalling complexSam Strickson, Kirsty F Houslay, Victor A Negri, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
Nature|June 9, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humansGalit Alter, Jingyou Yu, Jinyan Liu, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Cell|November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysDan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Pageof 25

Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
Nature|November 15, 2016
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeysErica N Borducchi, Crystal Cabral, Kathryn E Stephenson, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The Journal of Infectious Diseases|November 9, 2022
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Dan H Barouch, Christy Comeaux, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
The European Respiratory Journal|July 13, 2023
Oxidised IL-33 drives COPD epithelial pathogenesis <i>via</i> ST2-independent RAGE/EGFR signalling complexSam Strickson, Kirsty F Houslay, Victor A Negri, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
Nature|June 9, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humansGalit Alter, Jingyou Yu, Jinyan Liu, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Cell|November 19, 2013
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysDan H Barouch, Kathryn E Stephenson, Erica N Borducchi, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Pageof 25